Psych Atlanta — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$69,057	2
2024	Research	$64,514	14
2023	Research	$27,293	21
2022	Research	$14,208	28
2021	Research	$31,269	13
2020	Research	$75,220	13

Breakdown

Who paid Research payments · program years 2020–2025

Supernus Pharmaceuticals, Inc. $121,265 34 payments
E.R. Squibb & Sons, L.L.C. $117,951 5 payments
Janssen Research & Development, LLC $38,893 13 payments
Sumitomo Pharma America, Inc. $2,726 18 payments
Sunovion Pharmaceuticals Inc. $726 21 payments

Studies the money was for Research payments · program years 2020–2025

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Spn-812 in Adults With Attention- Deficit/Hyperactivity Disorder $69,767 26 payments
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $53,646 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of Spn-812 in Adults With Attention-Deficit/Hyperactivity Disorder (Adhd) $51,498 8 payments
67953964Mdd3004 $38,893 13 payments
Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) $30,565 1 payment
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $30,387 2 payments
Phase III OLE of KarXT in Adjuct Schiz (ARISE 2) - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $3,353 1 payment
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression) $2,336 3 payments
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. $726 21 payments
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. $390 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.